Trial Outcomes & Findings for Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's Disease (NCT NCT01467960)

Results Overview

Apolipoprotein D (apoD)concentration in human serum as a potential marker for Parkinson's disease (PD)

Recruitment status

UNKNOWN

Target enrollment

180 participants

Primary outcome timeframe

Baseline

Results posted on

2013-10-30

Participant Flow

90 healthy subjects are enrolled on the base of their age being classified in the groups I (20-40), II (40-65) and three (\>than 65). 90 patients are enrolled on the base of their disease's stage (Hoehn and Yahr classification) being classified in the groups A (I, H\&Y), B (II, H\&Y) and C (\> than II, H\&Y).

Participant milestones

Participant milestones
Measure	Group I 30 Healthy Subjects aged 20-40	Group II 30 Healthy Subjects aged 40-65	Group III 30 Healthy Subjects aged more than 65	Group A 30 Patients at Stage I, H\&Y classification	Group B 30 Patients at Stage II, H\&Y classification	Group C 30 Patients at Stage more than III, H\&Y classification
Overall Study STARTED	30	30	30	30	30	30
Overall Study COMPLETED	30	30	30	0	0	0
Overall Study NOT COMPLETED	0	0	0	30	30	30

Reasons for withdrawal

Reasons for withdrawal
Measure	Group I 30 Healthy Subjects aged 20-40	Group II 30 Healthy Subjects aged 40-65	Group III 30 Healthy Subjects aged more than 65	Group A 30 Patients at Stage I, H\&Y classification	Group B 30 Patients at Stage II, H\&Y classification	Group C 30 Patients at Stage more than III, H\&Y classification
Overall Study Enrollment of patients (PD) in 09/2013	0	0	0	30	30	30

Baseline Characteristics

Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's Disease

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Group I n=30 Participants Healthy Subjects aged 20-40	Group II n=30 Participants Healthy Subjects aged 40-65	Group III n=30 Participants Healthy Subjects aged more than 65	Group A n=30 Participants Patients at Stage I, H\&Y	Group B n=30 Participants Patients at Stage II, H\&Y	Group C n=30 Participants Patients at stage \> than II, H\&Y	Total n=180 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Age, Categorical Between 18 and 65 years	30 Participants n=5 Participants	30 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	60 Participants n=8 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	0 Participants n=7 Participants	30 Participants n=5 Participants	30 Participants n=4 Participants	30 Participants n=21 Participants	30 Participants n=8 Participants	120 Participants n=8 Participants
Sex: Female, Male Female	15 Participants n=5 Participants	15 Participants n=7 Participants	15 Participants n=5 Participants	15 Participants n=4 Participants	15 Participants n=21 Participants	15 Participants n=8 Participants	90 Participants n=8 Participants
Sex: Female, Male Male	15 Participants n=5 Participants	15 Participants n=7 Participants	15 Participants n=5 Participants	15 Participants n=4 Participants	15 Participants n=21 Participants	15 Participants n=8 Participants	90 Participants n=8 Participants
Region of Enrollment Italy	30 participants n=5 Participants	30 participants n=7 Participants	30 participants n=5 Participants	30 participants n=4 Participants	30 participants n=21 Participants	30 participants n=8 Participants	180 participants n=8 Participants

PRIMARY outcome

Timeframe: Baseline

Apolipoprotein D (apoD)concentration in human serum as a potential marker for Parkinson's disease (PD)